Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMX-8 for Anemia in Chronic Kidney Disease
NCT02228655Phase 1Terminated
- Sponsor
- FerruMax Pharmaceuticals, Inc.
- Start
- Oct 2014
- Primary completion
- Apr 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FMX-8 in anemia, sponsored by FerruMax Pharmaceuticals, Inc. Primary endpoint: Change in hemoglobin concentration at 57 days. Started Oct 2014; status: terminated.
02
Drugs
FMX-8
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02228655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228655.